Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TrivarX Limited ( (AU:TRI) ) has issued an announcement.
TrivarX Limited has completed patient recruitment for its clinical trial in collaboration with the Greater Los Angeles Research and Education Foundation and US Veterans Affairs Greater Los Angeles Healthcare System. The trial evaluates a novel single-lead ECG algorithm to screen for major depressive episodes in veterans with suspected sleep apnea. The completion of recruitment, following promising interim results, marks a significant milestone in validating the algorithm as a scalable, non-invasive mental health assessment tool. The company anticipates that full trial results will be available later this quarter, which will inform discussions with regulatory agencies and commercial partners.
More about TrivarX Limited
TrivarX Limited is a mental health technology company that focuses on pioneering the use of objective measures for early detection and screening of mental health conditions. Founded in Australia, it operates with offices in Perth and Minneapolis, and is listed on the Australian Securities Exchange and trades on the OTCQB Venture Market.
YTD Price Performance: 68.75%
Average Trading Volume: 3,821,648
Technical Sentiment Signal: Hold
Current Market Cap: A$16.74M
See more insights into TRI stock on TipRanks’ Stock Analysis page.